Management of Brain Metastases with Stereotactic Radiosurgery (SRS) and Surgery

Primary Indications Favoring SRS Over Surgery

The National Comprehensive Cancer Network recommends SRS for brain metastases that are small (<3 cm), deep-seated, multiple (1-4 lesions), or in patients with medical contraindications to craniotomy 1, 2
Lesions <3 cm in diameter are optimal for SRS, achieving local control rates of approximately 85% at 1 year and 65% at 2 years for small metastases 1, 2
Deep-seated lesions in eloquent brain regions are suitable for SRS, as surgical access carries high morbidity risk 1, 2, 3
SRS alone is the preferred treatment for 1-4 brain metastases in patients with good performance status (KPS >70) 4, 5

Primary Indications Favoring Surgery Over SRS

The National Comprehensive Cancer Network recommends surgery for lesions >3 cm diameter, large cystic or necrotic tumors, and tumors with prominent mass effect causing midline shift or neurologic deterioration 1, 2, 3
Obstructive hydrocephalus requiring immediate decompression is an indication for surgery 1, 2
Posterior fossa lesions with incipient brainstem or fourth ventricular compression are suitable for surgery, even if <3 cm 1, 2

Comparative Outcomes: SRS vs Surgery

Class I evidence supports surgery plus WBRT as superior to WBRT alone for single brain metastases 4, 6
Class III evidence shows equivalence in overall survival between SRS alone and surgery plus WBRT for single metastases 4, 6
Post-operative SRS to resection cavity improves local control without the neurocognitive decline associated with WBRT 5, 7

Prognostic Factors Influencing Treatment Selection

KPS >70 or RPA Class I-II are favorable factors for aggressive treatment (either modality) 4, 6, 8
Age <60-65 years and controlled primary tumor are also favorable factors for aggressive treatment 4, 6
KPS <70 patients should not receive radiation therapy, as median survival is <2 months with best supportive care only 8

Technical Considerations and Pitfalls

Fractionated SRS (2-5 fractions) should be used for lesions >3 cm or near critical structures to reduce toxicity 5
Distinguishing tumor recurrence from radiation necrosis requires advanced imaging (MR spectroscopy, perfusion, or PET) 9
En bloc resection decreases risk of leptomeningeal disease compared to piecemeal resection 4, 6
Gross total resection improves overall survival and prolongs time to recurrence in RPA Class I patients 4, 6

Recurrent Disease Management

Repeat SRS is reasonable if prior response was durable (>6 months) and imaging confirms active tumor versus necrosis 3
Class III evidence supports improved survival with craniotomy for recurrence after initial SRS, considering functional status, age, extracranial disease, and interval between SRS and recurrence 4, 6

Common Pitfalls to Avoid

Do not defer local therapy in asymptomatic brain metastases unless specific molecular alterations (EGFR, ALK, PD-L1) allow systemic therapy first 10, 8
Avoid WBRT at recurrence in patients who previously received WBRT due to neurotoxicity concerns 3
Multidisciplinary tumor board discussion is essential before treatment selection, as most patients die of systemic disease, not brain metastases 5

Fractionated Stereotactic Radiosurgery for Brain Metastases

Indications and Treatment Guidelines

For large brain metastases (>3 cm), fractionated SRS using 27 Gy in 3 fractions or 30 Gy in 5 fractions is recommended over single-fraction SRS to achieve superior local control while minimizing radiation necrosis risk, according to the American Association of Neurological Surgeons 11
The American Association of Neurological Surgeons recommends 27 Gy in 3 fractions for large lesions, yielding 1-year local control of 91% compared to 77% with single-fraction SRS 11
30 Gy in 5 fractions is an alternative regimen that achieves similar control with reduced necrosis risk, as suggested by the American Association of Neurological Surgeons 11
Single-fraction doses of 24 Gy achieve 85% 1-year control, but lower doses (15-18 Gy) result in <50% control, demonstrating the dose-response relationship, according to the American Association of Neurological Surgeons 11
Multifraction SRS reduces radionecrosis to 8% versus 20% with single-fraction for large lesions (p=0.004), as reported by the American Association of Neurological Surgeons 11

Treatment Algorithm by Lesion Size

For small lesions (<3 cm), standard single-fraction doses based on tumor diameter are recommended, with 24 Gy for <2 cm and 18 Gy for 2-3 cm, according to the American Association of Neurological Surgeons 11
For large lesions (>3 cm), fractionated SRS with 27 Gy/3 fractions or 30 Gy/5 fractions is recommended, as suggested by the American Association of Neurological Surgeons 11

Post-Operative Resection Cavities

SRS to the resection cavity reduces local recurrence and should be used routinely, according to the American Association of Neurological Surgeons 12

Number of Metastases Considerations

SRS alone is recommended over whole brain radiotherapy when cumulative volume <7 mL, as suggested by the American Association of Neurological Surgeons 12, 11
WBRT should be reserved for salvage therapy to preserve neurocognitive function, according to the American Association of Neurological Surgeons 11

Critical Pitfalls to Avoid

Do not use single-fraction doses <18 Gy for large lesions, as this results in <50% local control, as reported by the American Association of Neurological Surgeons 11
Do not attempt single-fraction SRS for lesions >3 cm due to prohibitive necrosis risk (20-23%), according to the American Association of Neurological Surgeons 11

Follow-up and Salvage

Routine MRI surveillance is mandatory to detect recurrence early for salvage therapy, as suggested by the American Association of Neurological Surgeons 11

Radiation Necrosis Rates: WBRT vs SRS vs fSRS

Comparative Radiation Necrosis Rates by Modality

The American Academy of Neurology and Neuro-Oncology societies acknowledge that radiation necrosis occurs in 5-35% of patients after single-session SRS, compared to approximately 5% after WBRT, with fractionated SRS (fSRS) reducing necrosis rates to 8% versus 20% for single-session SRS in large lesions 13, 14
The reported incidence of radiation necrosis with single-session SRS ranges from 5% to 35% in various retrospective series, reflecting inconsistencies in diagnostic criteria and institutional delivery patterns 13, 15, 16
For large lesions (>3 cm), single-session SRS carries a 20% radiation necrosis rate compared to 8% with multisession approaches, as recommended by the American Society for Radiation Oncology 14

Critical Factors Influencing Radiation Necrosis Risk

Postoperative SRS/SRT to resection cavities carries relatively high necrosis rates due to typically large volumes, generous expansions, and interdigitation with normal brain, according to the National Comprehensive Cancer Network 13, 17, 18
Dose escalation with hypofractionation demonstrates improved control without proportional increases in necrosis when properly fractionated, as stated by the American Society for Radiation Oncology 14, 19

Algorithmic Approach to Minimize Radiation Necrosis

For lesions <3 cm, single-session SRS with standard dosing is recommended, as radiation necrosis risk remains acceptable at 5-10%, according to the American Association of Neurological Surgeons 14
For lesions >3 cm, prioritizing fractionated SRS using 27 Gy in 3 fractions or 30 Gy in 5 fractions achieves superior local control (91% at 1 year) while minimizing necrosis (8%), as suggested by the Society for Neuro-Oncology 14

Common Pitfalls and Management

Radiation necrosis typically develops 3 months to 3 years after treatment and requires histopathologic confirmation or advanced imaging to distinguish from tumor recurrence, as stated by the National Cancer Institute 13, 15, 16
Critical avoidance strategies include never using single-fraction doses <18 Gy for large lesions and not attempting single-fraction SRS for lesions >3 cm, as recommended by the American Society for Radiation Oncology 14

Guideline for Selecting Stereotactic Radiosurgery vs. Whole‑Brain Radiation Therapy in Patients with Brain Metastases

1. Cumulative Tumor Volume as the Primary Selection Criterion

Total cumulative tumor volume is the single most important prognostic factor for treatment selection, outweighing lesion count. 20
Stereotactic radiosurgery (SRS) is recommended when the cumulative volume is < 7 mL, irrespective of the number of metastases (including cases with > 4 lesions). 21
Patients whose cumulative volume is < 7 mL and who have < 7 brain lesions achieve a median overall survival of ≈ 13 months, compared with ≈ 6 months when either threshold is exceeded. 20
A total treatment volume < 13 cc with no single metastasis larger than 3 cc predicts equivalent survival for patients with > 4 metastases as for those with 1–4 metastases. 22

2. Lesion Size and Fractionation Strategy

Individual lesions < 3 cm are best treated with single‑fraction SRS, providing a 1‑year local control rate of ≈ 85 %. 23
Lesions > 3 cm require fractionated SRS (e.g., 27 Gy in 3 fractions or 30 Gy in 5 fractions) to achieve ≈ 91 % 1‑year local control while lowering radiation‑necrosis risk from ≈ 20 % to ≈ 8 %. 23

3. Number of Metastases

For 1–4 metastases, SRS alone is the standard of care. 23
For > 4 metastases, SRS alone remains recommended provided the cumulative volume is < 7 mL. 21
When the total volume is < 13 cc, there is no survival difference between patients with > 4 metastases and those with 1–4 metastases. 22

4. Patient Performance Status

A Karnofsky Performance Status (KPS) > 70 is required for aggressive local therapy (SRS or WBRT). 20
Patients classified as RPA Class I–II derive the greatest benefit from SRS. 20

5. Primary Tumor Histology and Systemic Disease Control

Radiosensitive histologies—breast cancer, melanoma, renal cell carcinoma—achieve good local control with SRS regardless of the number of brain metastases. 20

6. Decision Algorithm Highlights

Step 1 – Cumulative Volume: If < 7 mL, proceed with SRS alone; if > 7 mL, consider WBRT or lesion‑selective SRS. 21
Step 2 – Lesion Size: All lesions < 3 cm → single‑fraction SRS; any lesion > 3 cm → fractionated SRS or surgical resection. 23
Step 3 – Performance Status: KPS > 70 permits definitive treatment; KPS ≤ 70 warrants best‑supportive care. 20

7. Avoiding Inappropriate Whole‑Brain Radiation Therapy

Initiating WBRT when SRS criteria are met leads to irreversible neurocognitive decline without a survival advantage. 22
Combining WBRT with SRS worsens cognitive function and quality of life compared with SRS alone. 21
Lesion number alone should not preclude SRS if volume thresholds are satisfied. 21
Single‑fraction SRS should not be used for lesions > 3 cm, given a ≈ 20 % risk of radiation necrosis. 23

Performance Status Criteria for Whole‑Brain Radiotherapy with Simultaneous Integrated Boost

Patient Selection

Patients should have a Karnofsky Performance Status greater than 70 (corresponding to RPA Class I–II) to be considered suitable candidates for whole‑brain radiotherapy combined with a simultaneous integrated boost to bulky brain metastases. 24